Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6070 + ifinatamab deruxtecan vs standard first-line therapy in extensive-stage small cell lung cancer
CTR20255221Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of gocatamig in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Mar 2026; status: active.
02
Drugs
gocatamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20255221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255221.